Welcome to the latest TREAT-NMD newsletter. This edition features information relating to the planned TREAT-NMD/EMEA meeting for Outcome Measures in SMA as well as news from two of our Industrial partners, Santhera and Summit.
As always, we hope you enjoy the newsletter and look forward to hearing your comments - write to info@treat-nmd.eu with anything you'd like to say. Feel free to forward this message to anybody you think might find it of interest, or invite them to sign up to receive the newsletter by visiting our website. Back-issues of this newsletter can be found on our website at http://www.treat-nmd.eu/patients/news/ezine-archive/
Best wishes,
Katie, Volker, Steve, Emma, Neville, Brigitta and Rachel: the Newcastle TREAT-NMD team
12-14 Sep 2008 EAMDA/TREAT-NMD conference
03-04 Oct 2008 European Research Conference in Paediatric Neurology
02-04 Feb 2009 TREAT-NMD Governing Board and Science and Technology Advisory Council Meetings
09-12 Sep 2009 IDMC-7 International Myotonic Dystrophy Consortium
 |
|
Newsletter Summer BreakDear Supporters, The TREAT-NMD newsletter will be taking a break over the summer and will return on Friday 12th September. As ever, if you would like to contribute to the newsletter please e-mail your suggestions to info@treat-nmd.eu. We wish you all a relaxing summer break! Best wishes, TREAT-NMD coordination team.
 |
TREAT-NMD / EMEA Workshop on clinical outcome measures and endpoints for efficacy assessment for SMATREAT-NMD Neuromuscular Network and EMEA, in collaboration with the US advocacy groups, ICC and the neuromuscular community, are planning to host a 1 day meeting at the EMEA office in London on Monday 13th October 2008. The meeting is aimed at creating a roadmap for trial readiness in SMA and appropriate outcome measures have been identified as a key point for discussion.
 MORE > |
Job opportunities at the Dubowitz Neuromuscular Centre in LondonFour separate job opportunities - clinical scientist, clinical trial coordinator, research physiotherapist and postdoc in congenital myopathies - are available at the Dubowitz Neuromuscular Centre of UCL's Institute for Child Health in London.  MORE > |
First Myotubular Trust call for projectsThe Myotubular Trust will be holding a first call for research projects in mid to late September 2008. Projects should aim to find a cure and / or a treatment for any of the three types of myotubular myopathy. Completed applications will be required by mid December 2008 and it is anticipated that awards will be made in April 2009.  MORE > |
BioMarin and Summit plc Sign Worldwide Licensing AgreementBioMarin Pharmaceutical Inc. and TREAT-NMD Partner Summit Corporation plc announced this week that they have entered into an exclusive worldwide licensing agreement for Summit’s novel preclinical candidate SMT C1100 and all follow-on molecules, which are being developed to treat Duchenne muscular dystrophy (DMD).  MORE > |
Santhera Pharmaceuticals Receives First Product ApprovalTREAT-NMD partner Santhera Pharmaceuticals has announced that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich’s Ataxia.  MORE > |
5th UK SMA Researchers' Meeting- Call for PapersA call for oral and poster presentations has been released for the meeting which is jointly supported by The Jennifer Trust and The SMA Trust.  MORE > |
Clinical trial/systematic review training opportunitiesSeveral training opportunities are available for those interested in systematic reviews and clinical trials. MORE > |
